Novo Nordisk A/S: FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity

        Print
| Source: Novo Nordisk A/S
Bagsværd, Denmark, 20 May 2014 - Novo Nordisk today announced that the US Food
and Drug Administration (FDA) has informed the company that an FDA Advisory
Committee meeting is tentatively scheduled to be held on 11 September 2014 to
discuss the New Drug Application (NDA) for liraglutide 3 mg for the treatment of
obesity. The NDA was submitted to the FDA on 20 December 2013.

For further information

 Media:

 Mike Rulis                  +45 4442 3573   mike@novonordisk.com

 Ken Inchausti (US)          +1 609 514 8316 kiau@novonordisk.com

 Investors:

 Kasper Roseeuw Poulsen      +45 3079 4303   krop@novonordisk.com

 Jannick Lindegaard Denholt  +45 3079 8519   jlis@novonordisk.com

 Lars Borup Jacobsen         +45 3075 3479   lbpj@novonordisk.com

 Daniel Bohsen               +45 3079 6376   dabo@novonordisk.com

 Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com


Company announcement No 35 / 2014


[HUG#1787460]